For citations:
Fedyanin M.Yu., Polyanskaya E.M., Elsnukaeva H.M., Tryakin A.A., Pokataev I.А., Ignatova Е.О., Sergeev U.S., Bulanov A.A., Tjulandin S.A. Is it necessary to add anti-angiogenic therapy to chemotherapy in patients with metastatic colorectal cancer and BRAF mutation? The systematic review and meta-analysis results. Malignant tumours. 2020;10(2):36-44. (In Russ.) https://doi.org/10.18027/2224-5057-2020-10-2-3